Follow GLAPY to never miss an important update.
Glanbia reported a strong quarter with earnings of $4.06 per share, well ahead of the $3.51 analysts expected. Revenue reached about 2.08 billion dollars. The company is seeing a boost from people using weight-loss drugs, who are often advised to eat more protein to keep their muscle mass while losing weight. This shift is turning protein supplements into a daily staple for more people.
Because of this demand, the company raised its profit forecast for the full year. This shows the business is successfully moving away from selling basic dairy ingredients and toward higher-margin brands like Optimum Nutrition. For someone holding the stock, this confirms that the shift into a pure-play health and wellness company is paying off with higher profits and a more predictable business model.
Management consistently sets conservative targets and clears them, with the most recent results showing the business is outrunning even their own raised expectations.
| Expectation | |
|---|---|
| EPS | $3.93 |
| Revenue | $2.15B |